Takuya Kawahara

Dr. Takuya Kawahara

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Open access
SIShohei Inui
Shohei Inui
RKRyo Kurokawa
Ryo Kurokawa
YNYudai Nakai
Yudai Nakai
YWYusuke Watanabe
Yusuke Watanabe
MKMariko Kurokawa
Mariko Kurokawa
OAOsamu Abe
Osamu Abe
Purpose To compare the performance and interobserver agreement of the COVID-19 Reporting and Data System (CO-RADS), the COVID-19 imaging reporting and data system (COVID-RADS), the RSNA expert cons...

1 September 2020 in Lung Cancer
Verified
Journal Article
Closed access
CSChangbo Sun
Changbo Sun
MAMasaki Anraku
Masaki Anraku
TKTakuya Kawahara
Takuya Kawahara
TKTakahiro Karasaki
Takahiro Karasaki
KKKentaro Kitano
Kentaro Kitano
JNJun Nakajima
Jun Nakajima

4 January 2022 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
TKTakuya Kawahara
Takuya Kawahara
NTNaruto Taira
Naruto Taira
TSTakeru Shiroiwa
Takeru Shiroiwa
YHYasuhiro Hagiwara
Yasuhiro Hagiwara
TFTakashi Fukuda
Takashi Fukuda
HMHirofumi Mukai
Hirofumi Mukai
Purpose: To establish minimal important differences (MIDs) for the European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 (EORTC QLQ-C30) in patients with metastatic breast cancer. Methods: The dataset was obtained from the SELECT BC-CONFIRM randomized clinical trial. Anchors obtained from patients (transition items) and clinicians (performance status) were used for anchor-based methods. Anchors obtained through 6 months after starting treatment were used for this analysis. Correlation coefficients of anchor and change in QLQ-C30 and effect size were used to qualify for estimating MIDs. Mean change method and generalized estimating equation were applied to estimate MIDs. Distribution-based methods were used for comparison. Results: We analyzed a dataset of 154 metastatic breast cancer patients. MIDs were estimated in 8 of 15 scales of QLQ-C30. Estimated MIDs for within-group improvement varied from 7 to 15 and those for deterioration varied from − 7 to − 17. Estimated MIDs for between-group improvement varied from 5 to 11 and those for deterioration varied from − 5 to − 8 across QLQ-C30 scales. Patient-reported anchors were more susceptible to early changes in health status than clinician-reported anchors. Conclusion: We provided the MIDs of the QLQ-C30 using both patient- and clinicians-reported anchors measured in a randomized trial of Japanese patients with metastatic breast cancer. We recommend patient-reported anchors for anchor-based estimation of MID. Our results can aid patients and clinicians, as well as researchers, in the interpretation of QLQ-C30.

1 December 2018 in Burns
Verified
Journal Article
Closed access
ATAsuka Tsuchiya
Asuka Tsuchiya
HYHayato Yamana
Hayato Yamana
TKTakuya Kawahara
Takuya Kawahara
YTYusuke Tsutsumi
Yusuke Tsutsumi
HMHiroki Matsui
Hiroki Matsui
HYHideo Yasunaga
Hideo Yasunaga

20 May 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
RNRyota Niikura
Ryota Niikura
TATomonori Aoki
Tomonori Aoki
TKTetsu Kojima
Tetsu Kojima
TKTakuya Kawahara
Takuya Kawahara
AYAtsuo Yamada
Atsuo Yamada
KKKazuhiko Koike
Kazuhiko Koike

1 August 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NTNaruto Taira
Naruto Taira
MSMasataka Sawaki
Masataka Sawaki
YUYukari Uemura
Yukari Uemura
TSTsuyoshi Saito
Tsuyoshi Saito
SBShinichi Baba
Shinichi Baba
FGfor the RESPECT Study Group
for the RESPECT Study Group
PURPOSEWe report findings on quality of life (QoL) in the RESPECT trial, which compared adjuvant trastuzumab monotherapy with trastuzumab plus chemotherapy in older patients with human epidermal gr...